| ￥3300 | |
| Z04155-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 38.2 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-53 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of CD14, His, Human is greater than 95% as determined by SEC-HPLC. »
CD14, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Human monocyte differentiation antigen CD14 is a pattern recognition receptor (PRR) that enhances innate immune responses. CD14 was first identified as a marker of monocytes to signal intracellular responses upon bacterial encounters. Given the absence of an intracellular tail, CD14 was doubted to have the signaling capacities. |
| Synonyms | CD14; CD14 molecule |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
